INSULIN RECEPTOR AND ITS SIGNALING
Insulin is a potent anabolic hormone that is synthesized and secreted from the b-cells of the islets of Langerhans in the pancreas, and then circulated throughout the blood stream. Insulin which consists of two polypeptide chains joined by disulfide bonds, play a vital role in cell growth and development, and maintenance of glucose homeostasis (White and Kahn, 1994; De Meyts, 2004) . The insulin receptor (IR) belongs to the receptor tyrosine kinase family with intrinsic tyrosine kinase activity.
IR is a heterotetrameric receptor composed of two extracellular a subunits and two membrane-spanning b subunits that are disulfide linked into an a2b2 configuration ( Fig. 1 ) (Becker and Roth, 1990; Lee and Pilch, 1994; Bevan, 2001) . The a subunits span the extracellular portion that contains the ligand-binding domain of the receptor, while the b subunits span extracellular, transmembrane, and intracellular domains. The intracellular domain of the b subunits, which expresses in-44 b-Adrenergic Receptor and Insulin Resistance in the Heart trinsic tyrosine kinase activity, is involved in signal transduction (Ullrich et al., 1985; Becker and Roth, 1990; De Meyts, 2004) .
Binding of insulin to the a subunits of the receptor activates the intracellular tyrosine kinase activity of the b subunits, resulting in transphosphorylation of one b subunit by the other on specific tyrosine residues, and then autophosphorylation at specific sites in the intracellular tail of the receptor which is followed by tyrosine phosphorylation of cytoplasmic substrate proteins such as Src-homology-2-containing (Shc) proteins and insulin receptor substrate (IRS) proteins (Becker and Roth, 1990; Lee and Pilch, 1994; Bevan, 2001; Taniguchi et al., 2006) . These substrate proteins interact with their effectors that amplify and extend the insulin signaling cascades (Fig. 2) . For example, the phosphorylated Shc induces mitogenesis (Sasaoka and Kobayashi, 2000) . Phosphorylation of IRS promotes the interaction of IRS with many signaling proteins including growth factor receptor-bound protein-2 (Grb-2) (Myers et al., 1994) , Src homology 2 (SH2) domain-containing protein tyrosine phosphatase (SHP-2) (Hayashi et al., 2004) , and phosphatidylinositol-3-kinase (PI3K) (Sarbassov and Peterson, 1998) to produce many biological responses. The binding of IRS proteins to Grb-2 leads to the activation of the extracellular regulated kinase-1 and -2 (ERK1/2) which promotes mitogenesis, cell growth, and differentiation.
In particular, insulin action is primarily dependent on the activation of PI3K. IRS interacts with PI3K, leading to activate the PI3K activity (Backer et al., 1992) . The activated PI3K then generates phosphatidylinositol 3,4,5-trisphosphate (PIP3) from the substrate phosphatidylinositol 4,5-bisphosphate (PIP2) on the plasma membrane, which regulates the activity of several protein effectors, including Akt (known as protein kinase B, PKB) and atypical isoforms of protein kinase C (aPKC) (Lee and Pilch, 1994; Bevan, 2001; Taniguchi et al., 2006) that control many aspects of cellular insulin action, including protein synthesis, glycogen synthesis, and glucose transporter (GLUT) translocation from intracellular to the cell surface and ultimately triggers glucose uptake into the cells (Czech and Corvera, 1999) . Activation of Akt leads to an increased glucose transport and persistent translocation of GLUT subtype 4 (GLUT4) to the plasma membrane in adipocytes (Kohn et al., 1996 (Kohn et al., , 1998 . In addition, stimulation of PKCζ or PKCλ induces GLUT4 translocation, whereas inhibition of PKCλ suppresses GLUT4 translocation Kotani et al., 1998) . GLUT4 is widely expressed in various tissues such as skeletal muscle, cardiac muscle and adipose tissue that constitute important sites of glucose utilization after food intake (Zhao and Keating, 2007) . In the basal condition, most GLUT4 is localized in the intracellular space. Upon stimulation of IRs, GLUT4 is rapidly translocated to the cell surface, where it facilitates inward transport of glucose from the circulation into the cells (Watson and Pessin, 2001) . Glucose that enters the cell is rapidly phosphorylated by hexokinase to generate glucose-6-phosphate (G-6-P), and is subsequently used for metabolism or stored in the cell as glycogen or triglyceride (TG). Hexokinase II is found in association with GLUT4 in skeletal and cardiac muscle and in adipose tissue (Postic et al., 1993) .
ACTIONS OF INSULIN
Downstream effects of insulin are initiated through the binding of insulin to the extracellular b subunits of its receptor and transmission of the signal across the plasma membrane that activates several insulin signaling pathway. Although the details linking between the second messengers to the metabolic effects of insulin are still under investigation, the metabolic effects of insulin action are well understood. IR is widely ex- Fig. 1 . Structure of insulin receptor. Insulin receptor is a heterotetrameric receptor that contains two a subunits, which is extracellular and has the ligand-binding domain, and two b subunits, which consist of extracellular, transmembrane and intracellular domains. The tyrosine kinase domain of the receptor is present at the intracellular b subunits. pressed on many cell types, implicating the broad array of biological responses to insulin (Fig. 3) . The tissues that are considered important for control of glucose homeostasis are liver, skeletal muscle and adipose tissues. In addition, the brain, pancreatic islets, and cardiac muscle are also main targets for insulin action.
The actions of insulin are anabolic, and insulin signaling is critical for promoting the uptake, utilization, and storage of the major nutrients (e.g., glucose, lipids, and amino acids), resulting in glycogenesis, lipogenesis, and protein synthesis. Insulin also inhibits the catabolism of these macromolecules. In the liver, insulin increases glucokinase activity, thereby mediating the phosphorylation and trapping of glucose in hepatocytes. The increased glucose uptake into the hepatocytes accelerates the glycogen synthesis, glycolysis, and fatty acid synthesis. Insulin also reduces hepatic glucose output through the reduction of gluconeogenesis and glycogenolysis. Moreover, insulin suppresses the production and secretion of very-lowdensity lipoprotein (VLDL) in the liver (Chirieac et al., 2000) . In muscle, insulin increases amino acid uptake, stimulates the ribosomal protein synthesis machinery, and promotes glycogen synthase activity and subsequent glycogen storage. In adipose tissue, insulin promotes the expression of lipoprotein lipase, which hydrolyzes TG from circulating lipoproteins for uptake into fat cells. In addition, insulin inhibits the release of free fatty acids (FFAs) from adipose tissue, increases TG and FFAs synthesis and also trigger glucose uptake into adipose tissue (Eckel et al., 2005) .
Furthermore, insulin has anti-atherogenic actions in blood vessels (Eckel et al., 2005) . Insulin enhances production of the vasodilator nitric oxide (NO) (Montagnani et al., 2002) , and exerts anti-inflammatory and anti-oxidative stress effects (Yu et al., 2011) . Insulin also inhibits platelet aggregation (Trovati and Anfossi, 1998) and plasminogen activator inhibitor type 1 (PAI-1) activity (Juhan-Vague et al., 1996) . Furthermore, insulin has been suggested to be a growth factor that induces vascular cell growth and synthesis of some matrix proteins (Feener and King, 1997; McFarlane et al., 2001) .
INSULIN RESISTANCE
Insulin resistance is presented as an insulin function deficiency whereby normal circulating concentrations of insulin are insufficient to induce signals regulating normal glucose absorption and glucose homeostasis of tissues and organs ed insulin receptor phosphorylates and activates substrate proteins such as Shc and IRS. Phosphorylation of Shc promotes the formation of Shc/Grb-2/SOS complex which stimulates MAP kinase pathway, resulting in mitogenesis, cell growth, and differentiation. Phosphorylated IRS proteins interact with many other signaling proteins including Grb-2 and PI3K, and change cellular function. PI3K catalyzes the formation of PIP 3 which, in turn, activates Akt and aPKC, and controls many aspects of insulin action, including protein synthesis, glycogen synthesis, and glucose transport via the translocation of GLUT4 to the plasma membrane. Glucose that enters the cells is rapidly phosphorylated by hexokinase enzymes to generate glucose-6-phosphate (G-6-P), and is subsequently utilized for metabolism and/or stored in the cells as glycogen or TG. Kashiwagi et al., 1983; 12 Ginsberg, 2000; 13 Lamounier-Zepter et al., 2006;  14 Mangmool et al., 2016; 15 Morisco et al., 2005; 16 Morisco et al., 2007; 17 Akikawa et al., 2000; 18 How et al., 2006;  19 Mazumder et al., 2004; 20 McFarlane et al., 2001; 21 Boudina et al., 2009 . The released insulin acts on insulin receptors located on the plasma membrane of target tissues (i.e., skeletal muscle, liver, adipose tissue and heart). In skeletal muscle, cardiac muscle, and liver, insulin promotes glucose uptake and storage as glycogen or TG. In adipose tissue, insulin promotes conversion of glucose to TG by increasing lipid synthesis. (Jellinger, 2007) . Thus, insulin resistance is a defect in insulin action. Insulin resistance is a key feature of type 2 diabetes and metabolic syndrome, and contributes to abnormalities in many tissues (Table 1) . Insulin resistance in muscle and fat is generally marked by a decrease in glucose clearance from the circulation. Insulin resistance in the liver generally refers to a blunted ability of insulin to suppress glucose production, leading to an overproduction of glucose through gluconeogenesis and glycogenolysis, which contribute to hyperglycemia and development of diabetes (Matthaei et al., 2000; DeFronzo, 2004) . In adipocytes, insulin resistance causes increased rates of lipolysis resulting in excessive breakdown of stored TG into FFAs, which is responsible for hyperlipidemia in the obese state (Boden and Shulman, 2002) . In skeletal muscle, insulin resistance causes the reduction in both glucose transport and glycogen synthesis, which leads to inhibit glucose clearance (DeFronzo and Tripathy, 2009) . At the cellular level, insulin resistance involves blunted steps in the signaling cascade from the IR tyrosine kinase to translocation of GLUT4, but the molecular mechanisms are incompletely defined. Insulin resistance is associated with inflammation, oxidative stress, cardiac remodeling, and endothelial dysfunction that results in diminished endothelial NO synthase (eNOS) expression leading to an increase in vascular tone (Scherrer et al., 1994; Kuboki et al., 2000) . Insulin resistance leading to hyperinsulinemia and hyperglycemia is a predictor and/or marker of cardiovascular diseases. Insulin resistance is a hallmark in diabetic patients (Olefsky et al., 1973) and is associated with hypertension (Reaven, 1991) , obesity (Mingrone et al., 1997) , heart failure (Swan et al., 1994 (Swan et al., , 1997 , and dilated cardiomyopathy (Shah and Shannon, 2003) . In non-ischemic heart failure patients, the prevalence of insulin resistance highly contributes to heart failure development (Witteles and Fowler, 2008) .
A previous study reported that fatty acids compete with glucose for substrate oxidation in isolated rat heart muscle and rat diaphragm muscle (Randle et al., 1963) . They speculated that an increase in fat oxidation might be responsible for insulin resistance in obese states. Moreover, lipid accumulation within skeletal muscle and liver inhibits tyrosine phosphorylation of IRS-1, resulting in blockade of IRS-1/PI3K interaction which, in turn, blunts PI3K activity (Savage et al., 2005) . Therefore, there is an association between insulin resistance found in type2 diabetes and the development of heart disease. It is believed that the relationship between heart disease and diabetes is bidirectional whereby heart disease induces insulin resistance, and vice versa.
INSULIN RESISTANCE CAUSES HEART DISEASE
The relationship between diabetes and heart disease are well established. Diabetic patients who are diagnosed at younger ages are at much greater risk for cardiovascular diseases (Hillier and Pedula, 2003) . The incidence rate of congestive heart failure in diabetic patients is much greater than patients without diabetes (Nichols et al., 2004) , emphasizing the demand of early diagnosis and an intensive treatment of diabetes for preventing the progression of cardiac dysfunction and heart disease. Alström syndrome is a rare autosomal recessively inherited disorder that affects many organs. In patients with Alström syndrome, metabolic disturbances begin in childhood including severe insulin resistance, hyperinsulinemia and type 2 diabetes. These abnormalities result in a potentially fatal dilated cardiomyopathy and congestive heart failure (Marshall et al., 2005) . Studies using isolated perfused heart preparations and cardiac myocytes have demonstrated insulin resistance in both human and animal models of the diabetic heart (Ohtake et al., 1995; Kolter et al., 1997) . Insulin resistance develops in the hearts of mice as early as after high-fat feeding that involves reduction in glucose uptake and GLUT4 expression in the heart (Park et al., 2005) . A condition of insulin resistance and dysregulation of glucose metabolism might induce pathological conditions such as systolic/diastolic dysfunction and cardiac remodeling (Park et al., 2005) . Moreover, cardiac insulin resistance reduces the metabolic efficiency of the heart, which can lead to contractile dysfunction (Belke et al., 2000; Mazumder et al., 2004) . In addition, impaired myocardial insulin signaling promotes oxidative stress and mitochondrial dysfunction in the heart (Boudina et al., 2009 ). Thus, a condition involving insulin resistance and the dysregulation of glucose metabolism might induce other pathological conditions, such as systolic/diastolic dysfunction and cardiac remodeling. Despite the importance of insulin resistance in the diabetic heart, the molecular mechanisms by which insulin resistance develops in the heart are not fully understood.
Heart failure is twice as high in diabetic men while five times as high in diabetic women. Furthermore, the prevalence of heart failure in elderly diabetic patients is high as 39% (Bell, 2003) . The cardiomyopathic heart in the setting of insulin resistance is the worst scenario for energy metabolism, as insulin resistance causes down-regulation of genes regulating glucose homeostasis and metabolism that consequently leads to a state of energy starvation, which promotes further deterioration in cardiac functions (Witteles and Fowler, 2008) . The reduction of GLUT4 expression in the myocardium can be found in patients who have insulin resistance with concomitant cardiac hypertrophy (Paternostro et al., 1999) . Furthermore, reduction in GLUT4 and increase in FFAs concentrations have also been found in ischemic patients with mild chronic heart failure (Murray et al., 2004) . Moreover, insulin resistance often precedes the development of heart disease due to the altered metabolic environment (e.g., altered ATP generation, increased FFA oxidation, and downregulation of genes for glucose oxidation). These abnormalities result in myocardial dysfunction and HF (Heck and Dutka, 2009 ). However, the pathophysiological consequences of insulin resistance to cause heart disease are incompletely understood.
HEART DISEASE INDUCES INSULIN RESISTANCE
The evidence for insulin resistance causing heart failure is more extensive than the reverse. Patients with coronary artery disease, heart failure, or a history of myocardial infarction are insulin resistant (Paternostro et al., 1996) . Patients with severe heart failure have been reported to exhibit insulin resistance, and the degree of insulin resistance has been associated with the severity of heart failure (Swan et al., 1997) . The mechanisms underlying the worsening of insulin resistance in patients with heart failure are not quite understood. The possible mechanisms include sympathetic overactivation, endothelial dysfunction, and increased circulating cytokines such as TNF-a (Coats and Anker, 2000; Heck and Dutka, 2009 ). The evi-dences that support the mechanisms for heart disease causing insulin resistance include sympathetic overactivation such as increased catecholamine secretion through bAR. Overstimulation of bAR leads to the inhibition of insulin-stimulated glucose uptake in cardiomyocytes (Mangmool et al., 2016) . It has been proposed that infarcted rat hearts have reduced rates of insulin-induced glucose uptake and GLUT4 protein levels (Murray et al., 2006) . In addition, cardiac glucose uptake is defective after myocardial ischemia and after chronic bAR stimulation (Ciccarelli et al., 2011) . Moreover, decreased GLUT4 expression has been observed in an animal model of cardiac hypertrophy (Paternostro et al., 1995) . Increased norepinephrine concentration is found in heart failure (Thomas and Marks, 1978) . Norepinephrine can cause the elevation of FFA through the stimulation of lipolysis (Paolisso et al., 1991) . In addition, an increase of plasma FFA levels stimulates cardiac sympathetic activity (Paolisso et al., 2000) and adversely affects insulin signaling, thereby reducing glucose utilization by cardiac muscle. In the same way, the detrimental metabolic effects following sympathetic overstimulation extend further inhibition of pancreatic insulin secretion and increased glucose production, both of which worsen hyperglycemia (Nonogaki, 2000) . Currently, the interrelationship between insulin resistance and heart disease has been an interest topic. Although many questions remain with regard to the relationship between insulin resistance and heart disease, a number of exciting future research and trial promise to contribute to the amelioration of heart disease prognosis.
PROLONGED STIMULATION OF bAR INDUCES CARDIAC INSULIN RESISTANCE
Previous studies have reported that up-regulation of bAR plays an important role in the pathogenesis of insulin resistance in several tissues, especially the heart (Morisco et al., 2005 (Morisco et al., , 2007 . Insulin resistance might be associated with sustained bAR stimulation and excessive sympathetic nerve activity leading to structural and functional abnormalities in the heart. Acute bAR stimulation physiologically augments cardiac contraction, whereas chronic stimulation of bAR promotes adverse cardiac remodeling leading to cardiac myocyte apoptosis, myocardial hypertrophy and heart failure (Rockman et al., 2002) . In isolated perfused rat hearts, decreased insulin sensitivity was observed following isoproterenol (ISO) infusion and was accompanied by decreased GLUT4 levels (Heather et al., 2009 ). This study demonstrated that ISO infusion impaired in vivo cardiac functions, induced hypertrophy and decreased both fatty acid and glucose metabolism, which are similar to the alterations observed in animal models of myocardial infarction (Heather et al., 2009 ). In addition, sustained and overstimulation of myocardial bAR trigger a state of insulin resistance in cardiomyocytes (Morisco et al., 2005) and in heart tissue (Mangmool et al., 2016) . Insulin resistance can be assessed by uptake of glucose, GLUT expression and translocation, insulin receptor-beta (IR-b) expression, and IRS-1 expression and phosphorylation. In our previous study (Mangmool et al., 2016) , we reported that sustained bAR stimulation induces cardiac insulin resistance through attenuation of glucose uptake and inhibition of GLUT4 synthesis in the heart.
Stimulation of bARs has a biphasic effect on insulin-induced glucose uptake in cardiomyocytes (Morisco et al., 2005) .
Rapid stimulation of bAR (within minutes) has synergistic effects on insulin-induced glucose uptake. This effect of bAR is mediated by phosphorylation of Akt at threonine 308 (Thr308) through protein kinase A (PKA)/Ca 2+ -dependent and PI3K-independent pathway, whereas insulin-induced Thr phosphorylation of Akt exclusively depends on PI3K (Morisco et al., 2005) . On the other hand, chronic stimulation of bAR inhibits both insulin-induced glucose uptake and autophosphorylation of the IRs which is mediated by serine 473 phosphorylation of Akt through PKA/Ca 2+ and PI3K-dependent pathways (Morisco et al., 2005) .
Catecholamines (i.e., epinephrine, norepinephrine) including glucagon, cortisol and growth hormone are up-regulated in patients with heart failure and likely play a role in the development of insulin resistance and alteration of glucose homeostasis (Lager, 1991; Nikolaidis et al., 2004) . Up-regulation of sympathetic nervous system (e.g., elevation of catecholamines) activity not only enhances the development of insulin resistance but also directly contributes to the progression of heart failure. Elevation of catecholamine levels also stimulates lipolysis, increasing circulating FFA levels and exacerbating insulin resistance (Nonogaki, 2000) . Treatment with carvedilol (bAR antagonist) could decrease the utilization of FFA with improved myocardial efficiency (Wallhaus et al., 2001; Nikolaidis et al., 2006) .
In addition, insulin-induced glucose uptake might be suppressed by epinephrine, norepinephrine, or isoproterenol (ISO) in adipocytes. This inhibition was characterized by stimulation of several subtypes of bARs (Klein et al., 1999) . Stimulation of bARs with epinephrine or norepinephrine reduced the amount of plasma membrane GLUT4 by inhibiting insulin-induced GLUT4 translocation in adipocytes. In the same way, stimulation of bAR in brown adipose tissue has the similar effects (Klein et al., 1999) . The inhibitory effect of catecholamines on insulin-induced glucose uptake has also been observed in rat skeletal muscle (Chiasson et al., 1981; Lee et al., 1997) .
The above results indicate that alterations of glucose homeostasis and insulin resistance are often associated with pathological conditions characterized by excessive activation of sympathetic nervous system and sustained stimulation of bARs. (Deibert and DeFronzo, 1980; Morisco et al., 2005; Cipolletta et al., 2009) . However, the exact molecular mechanism by which bAR mediates cardiac insulin resistance and changes in its signaling have not been fully elucidated.
A few studies have demonstrated that bAR-mediated insulin resistance may be induced through cAMP-and PKAdependent signaling pathways. For example, cAMP analogs inhibited insulin-stimulated glucose uptake in 3T3-L1 adipocytes and rat adipocytes (Kashiwagi et al., 1983; van Putten and Krans, 1985) . Moreover, the activation of adenylyl cyclase (AC) by forskolin prevented insulin-stimulated glucose transport in rat adipocytes (Joost and Steinfelder, 1987) . In 3T3-L1 adipocytes, treatment with either forskolin or 8-bromo-cAMP resulted in the down-regulation of GLUT4 mRNA (Kaestner et al., 1991) . Similarly, blockade of AC abolishes the inhibitory effect of ISO on insulin-stimulated glucose uptake and GLUT4 mRNA expression in rat cardiomyocytes (Mangmool et al., 2016) . Therefore, cAMP appears to be an important mediator of bAR-mediated insulin resistance in the heart. Cellular responses to cAMP might be associated with many cAMP effectors, including PKA and a cAMP-regulated guanine nucleotide exchange factor (Epac). Therefore, the divergent cellular responses induced by cAMP and their compartmentalization remain to be defined.
After agonist binding, the bAR can couple with the a subunit of heterotrimeric G protein (Gas), which results in activation of AC, followed by elevation of cAMP levels (Pierce et al., 2002) . There are at least two pathways induced by cAMP, a PKA-dependent and PKA-independent pathway including Epac (Bos, 2006; Oestreich et al., 2007) . Chronic stimulation of bAR inhibited both insulin-induced glucose uptake and the autophosphorylation of IRs, which is mediated by PKA/ Ca 2+ and PI3K-dependent pathways (Morisco et al., 2005) . In brown adipocytes, insulin-induced glucose uptake was inhibited by prestimulation of b3ARs (Klein et al., 1999) . This effect was mediated via a PKA-dependent signaling pathway. In cardiomyocytes, sustained bAR stimulation-mediated inhibition of insulin-induced glucose uptake and GLUT4 expression was not affected by Epac depletion or inhibition of its activity, whereas blockade of either AC or PKA activity strongly inhibited these effects (Mangmool et al., 2016) . Thus, the cAMP/ PKA-dependent signaling pathway plays a major role in the pathogenesis of insulin resistance that is associated with an overactive sympathetic system in the heart. Moreover, bAR stimulation impairs insulin signaling mechanism through an Akt-dependent pathway in the heart, demonstrating that Akt crucially contributes to the regulation of insulin sensitivity and plays a key role in bAR stimulated insulin resistance in cardiomyocytes (Morisco et al., 2005) . There is therefore ample evidence to link insulin resistance to up-regulation of the sympathetic nervous system.
SUBTYPE SPECIFICITY OF bARS ON CARDIAC INSULIN RESISTANCE
Insulin resistance is an underlying common feature of heart disease, probably consequent to chronic bAR stimulation (Morisco et al., 2005 (Morisco et al., , 2006 . Although all b1-, b2-and b3-ARs can couple to the Gs protein and stimulate AC, to generate the second messenger cAMP, there are considerable differences in their ability to activate downstream signaling pathways. For instance, the CaMKII-dependent induction of fetal genes and apoptotic pathways in cardiac myocytes is specifically mediated by b1ARs, but not b2ARs (Zhu et al., 2003; Sucharov et al., 2006) . In contrast, stimulation of b2ARs activates cell survival signals, whereas b1ARs elicit apoptotic pathways in cardiac myocytes (Communal et al., 1999) .
The b2AR is widely expressed in several tissues including the vasculature, liver, skeletal muscle, adipocytes, and cardiac muscle, and therefore participates in cardiac function and body metabolism. Indeed, epidemiological studies have shown an association of b2AR genetic polymorphism with obesity, diabetes, and hyperlipidemia Yamada et al., 1999; Iaccarino et al., 2005b) . bAR (but not aAR) stimulation attenuates insulin-induced glucose uptake by inhibiting GLUT4 translocation to the plasma membrane in 3T3-L1 adipocytes (Mulder et al., 2005) . This inhibitory effect on GLUT4 translocation is mediated at least by the b2-and b3-ARs. The insulin-induced tyrosine phosphorylation of IRs, IRS-1, and IRS-2 was reduced by stimulating b3ARs in brown adipose tissue (Klein et al., 1999) . In addition, insulininduced glucose uptake was completely blocked by stimulating b3ARs (Klein et al., 1999) . In HEK-293 cells that stably overexpressed b2AR, chronic b2AR stimulation resulted in impaired insulin-induced glucose uptake and IRS-1 phosphorylation (Cipolletta et al., 2009) . Moreover, overstimulation of b2ARs inhibited insulin-induced GLUT4 translocation in b2AR-overexpressing HEK-293 cells and rat cardiomyocytes (Mangmool et al., 2016) . Thus, b2AR is considered as the bAR subtype that interferes with insulin-mediated GLUT4 translocation in the heart. Moreover, the reduction of insulin-induced autophosphorylation of IRs in response to chronic bAR stimulation was associated with Thr phosphorylation of the b-subunit of IRs (Morisco et al., 2005) . In rat cardiomyocytes, ISO-induced phosphorylation of the b-subunit of IRs on Thr residues was mediated by the b1AR subtype (Morisco et al., 2005) . In contrast, our recent study showed that overstimulation of b2AR significantly reduced the ability of insulin to induce glucose uptake and the translocation of GLUT4 in cardiomyocytes and heart tissue (Mangmool et al., 2016) . That previous study showed that ISO-induced phosphorylation of IR on Thr residues was inhibited by propranolol (a non-selective b-blocker) and betaxolol (a selective b1AR antagonist), whereas pretreatment with ICI118,551 (a specific b2AR antagonist) did not affect this response. These results suggest that b1AR selectively mediates Thr phosphorylation of IR after long term stimulation by ISO in rat neonatal cardiomyocytes (Morisco et al., 2005) . Nonetheless, the mechanisms by which b1AR stimulation inhibits the insulin-mediated phosphorylation of IRs, and stimulation of b2AR suppresses insulin-induced glucose uptake and GLUT4 translocation in cardiomyocytes have not been fully resolved.
Even though b1AR and b2AR share 54% sequence identity, the C-terminus (CT) tail of these two subtypes play different roles in receptor endocytosis and signaling pathways. The binding affinity of b-arrestin1 and 2 to the CT tail of the b1AR is lower than that for the b2AR (Shiina et al., 2000) . A chimeric b2AR containing the C-tail region of b1AR loses its ability to promote b-arrestin2-mediated ERK nuclear translocation (Kobayashi et al., 2005) . In addition, b1ARs and b2ARs have different PDZ-binding motifs within their CT tail leading to the recruitment of unique regulatory proteins when stimulated by their agonists. For example, the Na + /H + exchanger regulatory factor (NHERF) binds to a DSLL motif in the CT tail of b2ARs to stimulate Na + /H + exchange (Hall et al., 1998) , whereas Nmethyl-D-aspartate receptor binds to an ESKV motif within the CT of b1ARs and promotes receptor internalization (Hu et al., 2000) . The CT tail of b1AR, but not b2AR, mediates a unique conformation of b-arrestin that allows scaffolding of Epac and CaMKII to form a stable complex, leading to the subsequent cAMP/Epac-mediated activation of CaMKII (Yoo et al., 2009; Mangmool et al., 2010) . It is still unknown how the CT tail of bARs (both b1-and b2-AR) regulates bAR-mediated insulin resistance in the heart.
THE ROLE OF GRK ON CARDIAC INSULIN RESISTANCE
bARs belong to the GPCR family. Agonist binding of bAR leads to a dissociation of the heterotrimeric G protein into Ga and Gbγ subunits, both of which activate several effectors (Pierce et al., 2002) . In parallel, agonist stimulation also triggers the termination of GPCR signals with rapid attenuation of receptor responsiveness, termed as receptor desensitization. This process is initiated by GRKs that specifically bind to and phosphorylate the agonist-occupied receptors (Benovic et al., 1986) . GRK-mediated phosphorylation promotes the binding of b-arrestins to the receptors, and b-arrestins sterically inhibit further interactions of the receptors with G proteins (Ferguson et al., 1996) . The b-arrestin-bound receptors are then internalized from the plasma membrane via clathrin-coated vesicles (Krupnick and Benovic, 1998) . Overexpression of GRK enhances the bAR-mediated b-arrestin translocation to the plasma membrane and bAR internalization (Mangmool et al., 2006) .
Based on sequence and structural homology, the members of the GRK family can be subdivided into the following three groups: rhodopsin kinase subfamily (GRK1 and GRK7); bARK subfamily (GRK2 and GRK3); and GRK4 subfamily (GRK4, GRK5, and GRK6) (Penn et al., 2000) . GRKs are composed of three distinct domains as follows: (1) a highly conserved centrally located catalytic domain flanked by (2) an amino-terminal domain that includes a region of homology to the regulator of G protein signaling (RGS) protein and (3) a carboxylterminal domain of various lengths (Penela et al., 2003) .
GRK expression and activity has been found to be altered in heart disease. It has been shown that GRK2 synthesis and its activity are increased in the failing heart with consequent decrease in b1AR levels (Ungerer et al., 1993) . Increased GRK2 expression and activity was found in cardiomyocytes from patients with heart failure (Ungerer et al., 1994) . Moreover, overexpression of GRK2 reduces the response to bAR stimulation as a result of increased receptor desensitization (Koch et al., 1995) . Inhibition of GRK2 activity enhanced cardiac contractility and bAR responsiveness (Koch et al., 1995; Akhter et al., 1998) , confirming the essential role of GRK2 in mediating bAR desensitization. Beyond its classical function on receptor desensitization, GRK2 mediates the inhibitory effects of bAR on insulin signaling (Usui et al., 2004b; Cipolletta et al., 2009) , through mechanisms that are still subject to debate. In animal models of diabetes (both Zucker diabetic fatty rats and db/db mice), inhibition of GRK2/3 through synthetic peptides (derived from a kinase-substrate interaction site in GRK2/3) rescues glucose tolerance and enhances insulin sensitivity (Anis et al., 2004) , suggesting that GRK2 phosphorylates an unknown substrate to induce impaired glucose tolerance. It is interesting to note that GRKs are ubiquitously expressed in mammalian tissues, and their activities and production are increased in conditions characterized by chronic adrenergic activation, such as human congestive heart failure (Iaccarino et al., 2005a) and hypertension (Izzo et al., 2008) . For example, GRK2 is up-regulated through chronic bAR activation (Iaccarino et al., 2001 ). All the above considerations support the hypothesis that GRK2 is involved in the progression of insulin resistance induced by chronic bAR activation.
Endothelin-1 (ET-1) treatment leads to an enhanced IRS-1 degradation, a decreased tyrosine phosphorylation of IRS-1 and a decreased insulin-stimulated glucose transport in 3T3-L1 adipocytes (Ishibashi et al., 2001) . Insulin-induced GLUT4 translocation was inhibited by pretreatment with ET-1 for 24 h. This inhibitory effect was rescued by microinjection of anti-GRK2 antibody or GRK2 short interfering RNA (Usui et al., 2005) , suggesting a potential role of GRK2 on insulin resistance. Overexpression of kinase dead GRK2 mutant, but not wild-type GRK2, inhibited ET-1-induced serine 612 phosphorylation of IRS-1 and restored activation of this pathway.
Moreover, overexpression of the kinase dead GRK2 mutant suppressed ET-1-induced IRS-1 degradation, whereas wildtype-GRK2 did not, demonstrating a potential role for GRK2 kinase activity in this mechanism. Inhibition of GRK2 could also rescue the ET-1-induced insulin resistance (Usui et al., 2005) . Taken together, these results suggest that GRK2 mediates ET-1-induced insulin resistance by its kinase activity on IRS-1 serine phosphorylation and degradation.
Treatment with insulin causes tyrosine phosphorylation of IRS-1 and induces glucose uptake in human kidney embryonic (HEK-293) cells (Cipolletta et al., 2009) . Overexpression of b2AR increases GRK2 expression that is associated with significant deficit of IRS1 activation and glucose uptake by insulin (Cipolletta et al., 2009) . Similarly, overexpression of GRK2 prevents insulin-induced tyrosine phosphorylation of IRS1 and insulin-induced glucose uptake. This study also found that GRK2 interacts with IRS1, but not IR (Cipolletta et al., 2009) . These results provide a regulatory network between insulin signaling and GRK2 in which GRK2 kinase activity mediates bAR-induced insulin resistance and that inhibition of GRK2 activity leads to enhanced insulin sensitivity both in cell and animal models of insulin resistance.
Chronic stimulation of bAR signaling or marked overexpression of b2ARs causes the development of insulin resistance through an increase in GRK2 expression levels. GRK2 may function as a key negative regulator of insulin responsiveness. In endothelial cells, insulin stimulates a signaling pathway which leads to elevation of NO through the activation of endothelial NO synthase (eNOS) and subsequently promotes vasodilation (Kuboki et al., 2000) . A recent study showed that the interaction between GRK2 and Akt inhibited the phosphorylation of Akt on Thr 308, resulting in decreased eNOS phosphorylation and a consequent reduction of NO production (Taguchi et al., 2012) . However, the precise mechanism for GRK2 binding to IR and formation of the complex with IR and/or Akt remains to be elucidated. Recently, Luan et al. (2009) reported that insulin stimulates the formation of a new b-arrestin2 signal complex in which b-arrestin2 acts as a scaffold for the translocation of Akt to IR, even though insulin is not a GPCR. In contrast, Taguchi et al. (2012) demonstrated that up-regulation of GRK2 and a decrease in b-arrestin2 inhibited insulin-induced stimulation of Akt/eNOS signaling and that GRK2 overactivation may be induced by an increase in PKC activity in aortas from diabetic mice with hyperinsulinemia. In the normal aorta, b-arrestin2 binds to Akt under insulin stimulation. In contrast, insulin causes translocation of GRK2 to the plasma membrane in diabetes, where it binds to Akt and prevents b-arrestin2 from binding to Akt as GRK2 remains bound (Taguchi et al., 2012) . As mention above, previous studies have described a relationship between insulin resistance and increased GRK2 levels in pathological conditions. GRK2 inhibition can improve glucose uptake and insulin resistance in the heart (Ciccarelli et al., 2011) . Thus, GRK2 inhibitor (e.g., bARKct; C-terminus of bAR kinase) could be used for the possible treatment of insulin resistance in the heart.
THE ROLE OF b-ARRESTINS ON INSULIN RESISTANCE
b-Arrestins are key regulators of bAR (G protein-coupled receptor) endocytosis and trafficking, and G protein-indepen-dent signaling. b-Arrestins interact with agonist-occupied and phosphorylated receptors and inhibit further G protein activation (Ferguson et al., 1996) . Beyond their classical function, b-arrestins also function as scaffolding proteins linking receptors to several effectors such as ERK1/2, JNK, Src and Mdm2, an ubiquitin ligase (Lefkowitz and Shenoy, 2005; Lefkowitz et al., 2006) . The scaffolding of Ca 2+ /calmodulin kinase II (CaM-KII) and Epac by b-arrestin with subsequent translocation of this multimeric complex to agonist-occupied b1ARs is an essential mechanism for b1AR-mediated CaMKII activation (Mangmool et al., 2010) .
Insulin resistance is a central feature of type 2 diabetes and is caused by a deficiency in IR signaling. Luan et al. (2009) reported that the amount of b-arrestin2 was decreased either in a mouse model of type 2 diabetes (db/db) or in liver samples from diabetic patients. Deletion of b-arrestin2 induces insulin resistance, whereas overexpression of b-arrestin2 restores insulin sensitivity (Luan et al., 2009) . They also found that b-arrestin 2 forms the complex with Akt and Src after insulin stimulation which is consistent with previous studies reporting that b-arrestin interacts with Akt (Beaulieu et al., 2005) and Src (Luttrell et al., 1999) . This association between Src and Akt was reduced in liver samples from b-arrestin 2 KO mice, leading to the disturbance of insulin signaling and development of insulin resistance. In addition, insulin-stimulated phosphorylation of Akt, GSK3b and Foxo1 were reduced in livers of b-arrestin2 KO mice while increased in b-arrestin2 transgenic mice (Luan et al., 2009) , emphasizing that b-arrrestin2 controls the insulin signaling pathway.
In addition to b-arrestin2, b-arrestin1 also plays a role in insulin signaling and insulin resistance. Overexpression of b-arrestin-1 attenuated insulin-induced IRS-1 degradation, leading to enhanced insulin signaling downstream of IRS-1. Whereas insulin-induced degradation of IRS-1 was increased in cells treated with b-arrestin1 siRNA, stimulation of IR promotes the formation of a complex between IRS-1 and Mdm2, an E3 ubiquitin ligase enzyme, and this complex could be inhibited by b-arrestin1, resulting in a decreased ubiquitin content of IRS-1 (Usui et al., 2004a) . From these results, they postulated that both b-arrestin1 and IRS-1 competitively bind to Mdm2, which can ubiquitinate IRS-1. Moreover, dephosphorylation of S412 on b-arrestin and the amino terminus of b-arrestin1 are required for this effect of b-arrestin on IRS-1 degradation (Usui et al., 2004a) . Inhibition of b-arrestin1 leads to enhanced IRS-1 degradation and accentuates cellular insulin resistance.
TREATMENT WITH b-BLOCKERS IMPROVES bAR-MEDIATED CARDIAC INSULIN RESISTANCE
b-Blockers are widely used to treat heart failure, angina and myocardial infarction. They act by blocking the overstimulation of catecholamine to bAR in the heart (Bangalore et al., 2007) . During heart failure, a large amount of catecholamine is released from synaptic ends and this exerts harmful effects on the heart. Considering that bAR mediates cardiac insulin resistance as shown in previous studies (Morisco et al., 2005; Ciccarelli et al., 2011; Mangmool et al., 2016) , b-blockers are expected to exert beneficial effects by suppressing insulin resistance in the heart. Propranolol and metoprolol were able to abolish ISO inhibition of insulin-induced glucose uptake, GLUT4 expression, and GLUT4 translocation, whereas atenolol had no effect. The differential potency of these b-blockers might be due to differences in their affinity to bAR subtypes. We show that ISOmediated cardiac insulin resistance involves b2AR; hence, a b-blocker that has a higher affinity for b2AR could potentially exert an increased beneficial effect. Propranolol was found to antagonize both the b1AR and b2AR subtypes, while atenolol to the G protein-mediated activation of AC and cAMP generation. cAMP directly binds to and activates PKA. In b 2 AR signaling, PKA phosphorylates GRK2, which subsequently increases GRK2 activity. This leads to the inhibition of insulin-induced GLUT4 expression and the translocation of GLUT4 to the plasma membrane, thereby interfering with glucose uptake into cells and insulin-induced IRS1 phosphorylation. In b1AR signaling, PKA and PI3K activate Akt by phosphorylation at Ser 473, which in turn, phosphorylates the b subunit of insulin receptor (IRb) at Thr residues. Tyrosine phosphorylation of IRb inhibits insulin-induced tyrosine autophosphorylation of IRb, leading to impairment of insulin signaling. These conditions lead to insulin resistance in the heart. Treatment with b-blockers antagonizes ISO-mediated insulin resistance in the heart. and metoprolol displayed a selectivity for b1AR (Hoffmann et al., 2004) . Previous studies have investigated the Ki values by bAR binding assay and showed that various b-blockers have different Ki values for human b2AR: propranolol (0.8 nM), metoprolol (2,960 nM), and atenolol (8,140 nM) (Hoffmann et al., 2004) . Moreover, the offset in activity induced by b-blockers in the heart is related to their lipophilicity (Doggrell and Henderson, 1998) . The bAR blocking activity of atenolol, which exhibits low lipophilicity, was offset more quickly than that of propranolol, which exhibits high lipophilicity on contractile responses to ISO (Doggrell and Henderson, 1998) . Collectively, propranolol showed a more superior effect than atenolol and metoprolol in suppressing b2AR-mediated insulin resistance.
Interestingly, in addition to blocking bAR effects, some b-blockers have been shown to evoke signal transduction through the bARs in G protein-independent and b-arrestindependent manner (Wisler et al., 2007; Nakaya et al., 2012) . Long-term administration of metoprolol to mice induced cardiac fibrosis through b-arrestin2 and GRK5-dependent pathway (Nakaya et al., 2012) . Although metoprolol induces cardiac fibrosis, it still has a beneficial effect on heart failure by inhibiting catecholamine overstimulation in heart failure. Thus, it will be worthwhile to determine G protein-independent signal transduction of b-blockers on cardiac insulin resistance. However, some b-blockers have additional effects in addition to bAR blockades, such as intrinsic sympathomimetic activity, and antioxidant and vasodilating properties. Thus, these additional effects of b-blockers require further study for their ability to attenuate bAR-mediated insulin resistance in the heart.
SUMMARY
Based on data from previous studies, we propose that sustained and overstimulation of bARs leads to the development of heart failure and is associated with the pathogenesis of insulin resistance in the heart. Overstimulation of b2ARs enhances insulin resistance in the heart by inhibiting insulininduced glucose uptake, GLUT4 synthesis, and translocation of GLUT4 to the plasma membrane via the cAMP/PKA/GRK2-dependent pathway (Fig. 4) . As treatment with b-blockers such as propranolol and metoprolol could antagonize the effects of ISO-mediated cardiac insulin resistance in the heart, b-blockers may exert beneficial effects that can improve insulin resistance in the heart. Moreover, inhibition of GRK2 by bARKct gene therapy could be used for the improvement of glucose uptake in the heart.
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